302 related articles for article (PubMed ID: 20854964)
1. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
Wachtell K; Palmieri V; Gerdts E; Bella JN; Aurigemma GP; Papademetriou V; Dahlöf B; Aalto T; Ibsen H; Rokkedal JE; Devereux RB
Am J Cardiol; 2010 Oct; 106(7):999-1005. PubMed ID: 20854964
[TBL] [Abstract][Full Text] [Related]
2. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
[TBL] [Abstract][Full Text] [Related]
3. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
[TBL] [Abstract][Full Text] [Related]
5. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
[TBL] [Abstract][Full Text] [Related]
6. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
7. Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Palmieri V; Okin PM; Bella JN; Wachtell K; Oikarinen L; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2006 Oct; 24(10):2079-84. PubMed ID: 16957569
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
9. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
[TBL] [Abstract][Full Text] [Related]
11. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
[TBL] [Abstract][Full Text] [Related]
12. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
14. [Effect of cilazapril therapy on diastolic filling and left ventricular hypertrophy in patients with arterial hypertension].
De Simone R; Irace L; Perna B; Caruso C; Guida M; Iacono A
Minerva Cardioangiol; 1993 May; 41(5):205-9. PubMed ID: 8355860
[TBL] [Abstract][Full Text] [Related]
15. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
16. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
[TBL] [Abstract][Full Text] [Related]
17. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular hypertrophy determines the severity of diastolic dysfunction in patients with nonvalvular atrial fibrillation and preserved left ventricular systolic function.
Moon J; Rim SJ; Cho IJ; Lee SH; Choi S; Chung WJ; Byun YS; Ryu SK; Pyun WB; Kim JY
Clin Exp Hypertens; 2010; 32(8):540-6. PubMed ID: 21091364
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of left ventricular mass change during treatment of hypertension.
Devereux RB; Wachtell K; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris K; Aurup P; Dahlöf B
JAMA; 2004 Nov; 292(19):2350-6. PubMed ID: 15547162
[TBL] [Abstract][Full Text] [Related]
20. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
Rakić D; Rumboldt Z; Bagatin J; Polić S
Croat Med J; 2002 Dec; 43(6):672-9. PubMed ID: 12476475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]